Suggested remit: To appraise the clinical and cost effectiveness of icosapent ethyl within its marketing authorisation for preventing cardiovascular events due to elevated triglycerides.
Status Proposed
Process STA 2018
ID number 3831

Project Team

Project lead Emily Richards

Email enquiries


Key events during the development of the guidance:

Date Update
25 September 2020 - 23 October 2020 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance